Kwan Yoon
Partner @ BlueRun Ventures
Kwan Yoon is a Series A investor at BlueRun Ventures focused on Retail and Battery. Kwan Yoon is the Partner at BlueRun Ventures. He studied at Stanford University.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Kwan Yoon invests in
Stages Kwan Yoon invests in
Countries Kwan Yoon invests in
Investment Focus
Industry
- Retail 1 (14%)
- Battery 1 (14%)
- Fashion 1 (14%)
- Medical 1 (14%)
- Women's 1 (14%)
Stage
- Series A 2 (29%)
- Series B 2 (29%)
- Seed 1 (14%)
- Series C 1 (14%)
Country
- United States 4 (57%)
- Singapore 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Silicon Box
|
Silicon Box is an advanced OSAT (outsourced semiconductor assembly and testing) services provider, specializing in semiconductor integration. The company is capable of delivering full execution for semiconductor packaging, from initial design to final manufacturing of standard single chip packages to the most sophisticated chiplet-based systems,enabling applications that include AI (artificial intelligence), HPC (high performance computing), EV (electric vehicles), automotive, power management, mobile chipsets and processors, applications processors, radiofrequency, and more. | $200M / Series B / Jan 04, 2024 | |
Verismo Therapeutics
|
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates inpreclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer. | $7M / Seed / Feb 28, 2023 | |
|
Verismo Therapeutics
|
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates inpreclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer. | $7M / Seed / Feb 28, 2023 | |
Swiftly
|
Swiftly is the AI platform purpose-built for retail, serving retailers, wholesalers, and brands. Swiftly's AI agents unify data, automate workflows, and power the marketing that drives measurable growth — connecting shopper engagement, operations, and personalized experiences into one intelligent platform. Swiftly AI is built on theindustry's largest proprietary retail dataset: live transactions, 9 million products, and the closed-loop campaign outcomes of 33,000 stores. That foundation powers faster decisions, smarter execution, and AI-native experiences across the retail ecosystem. Trusted by leading retailers, wholesalers, and hundreds of iconic brands, Swiftly accelerates growth, reduces operational drag, and sets a new standard for what AI can do in retail. | $100M / Series C / Sep 19, 2022 | |
bolttech
|
Bolttech is an InsurTech company developing an AI-based point of sale insurance platform to offer a technology-enabled ecosystem for protection and insurance. Its platform also offers device protection, travel, motor, property and life insurance, and digital insurance to consumers. | $67.2M / Series A / Dec 06, 2021 | |
Qnovo
|
Qnovo is redefining the foundation of mobility and technology for a more resilient and mobile future—the lithium-ion battery. Since 2010, Qnovo has enabled the electrification revolution with its intelligent battery management software and predictive analytics that improves the performance of electric vehicles, energy storage systems, and consumerdevices with enhanced health and safety. Qnovo is working with the world’s top automotive OEMs, holds over 50 patents in the space, and the first generation of Qnovo technology is on more than 150 million smartphones worldwide. The company is headquartered in Milpitas, California. Its investors include BorgWarner, OGCI Climate Investments, Constellation Technology Ventures, BlueRun Ventures, U.S. Venture Partners and RockPort Capital. Visit www.qnovo.com. | $8.6M / Series B / Aug 02, 2015 | |
Hollywood Interactive Group
|
Hollywood Interactive Group is a privately held company that operates primarily through MyHollywood. | $5M / Series A / Sep 18, 2008 |
Co-Investors
About BlueRun Ventures
BlueRun Ventures is a venture capital firm with offices in the United States, Shanghai, Beijing, and Korea. BlueRun invests in information technology, mobile, and consumer technologies, with an emphasis on mobile opportunities. BRV has invested in over 160 companies, with select exits from PayPal (acquired by eBay), Waze (acquired by Google),Topsy (acquired by Apple), Coupa (NASDAQ: COUP), and more. In 2005, BlueRun changed its name from Nokia Venture Partners. While branded as Nokia Venture Partners, the firm helped to build emerging market leaders such as Airgo, Bitfone, Cornice, PayPal, Wavemarket, and WiderThan.
BlueRun Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Malloy
General Partner & Founder
|
|||
Jonathan Ebinger
General Partner
|
|||
Jui Tan
Partner
|
|||
|
Kwan Yoon
Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kwan Yoon invest in?
Kwan Yoon invests primarily in Retail, Battery and Fashion startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Kwan Yoon last invest?
The most recent investment recorded for Kwan Yoon closed in Jan 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
